No abstract

Tissue-resident macrophages are a diverse population of cells that perform specialized functions including sustaining tissue homeostasis and tissue surveillance. Here, we report an interstitial subset of CD169+ lung-resident macrophages that are transcriptionally and developmentally distinct from alveolar macrophages (AMs). They are primarily localized around the airways and are found in close proximity to the sympathetic nerves in the bronchovascular bundle. These nerve- and airway-associated macrophages (NAMs) are tissue resident, yolk sac derived, self-renewing, and do not require CCR2+ monocytes for development or maintenance. Unlike AMs, the development of NAMs requires CSF1 but not GM-CSF. Bulk population and single-cell transcriptome analysis indicated that NAMs are distinct from other lung-resident macrophage subsets and highly express immunoregulatory genes under steady-state and inflammatory conditions. NAMs proliferated robustly after influenza infection and activation with the TLR3 ligand poly(I:C), and in their absence, the inflammatory response was augmented, resulting in excessive production of inflammatory cytokines and innate immune cell infiltration. Overall, our study provides insights into a distinct subset of airway-associated pulmonary macrophages that function to maintain immune and tissue homeostasis.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of Coronavirus Disease 2019 (COVID-19). There is a dire need for novel effective antivirals to treat COVID-19, as the only approved direct-acting antiviral to date is remdesivir, targeting the viral polymerase complex. A potential alternate target in the viral life cycle is the main SARS-CoV-2 protease 3CLpro (Mpro). The drug candidate PF-00835231 is the active compound of the first anti-3CLpro regimen in clinical trials. Here, we perform a comparative analysis of PF-00835231, the pre-clinical 3CLpro inhibitor GC-376, and the polymerase inhibitor remdesivir, in alveolar basal epithelial cells modified to express ACE2 (A549+ACE2 cells). We find PF-00835231 with at least similar or higher potency than remdesivir or GC-376. A time-of-drug-addition approach delineates the timing of early SARS-CoV-2 life cycle steps in A549+ACE2 cells and validates PF-00835231’s early time of action. In a model of the human polarized airway epithelium, both PF-00835231 and remdesivir potently inhibit SARS-CoV-2 at low micromolar concentrations. Finally, we show that the efflux transporter P-glycoprotein, which was previously suggested to diminish PF-00835231’s efficacy based on experiments in monkey kidney Vero E6 cells, does not negatively impact PF-00835231 efficacy in either A549+ACE2 cells or human polarized airway epithelial cultures. Thus, our study provides in vitro evidence for the potential of PF-00835231 as an effective SARS-CoV-2 antiviral and addresses concerns that emerged based on prior studies in non-human in vitro models. Importance: The arsenal of SARS-CoV-2 specific antiviral drugs is extremely limited. Only one direct-acting antiviral drug is currently approved, the viral polymerase inhibitor remdesivir, and it has limited efficacy. Thus, there is a substantial need to develop additional antiviral compounds with minimal side effects and alternate viral targets. One such alternate target is its main protease, 3CLpro (Mpro), an essential component of the SARS-CoV-2 life cycle processing the viral polyprotein into the components of the viral polymerase complex. In this study, we characterize a novel antiviral drug, PF-00835231, which is the active component of the first-in-class 3CLpro-targeting regimen in clinical trials. Using 3D in vitro models of the human airway epithelium, we demonstrate the antiviral potential of PF-00835231 for inhibition of SARS-CoV-2.

Highlights d Controlled release of lab mice into the wild alters the state of the immune system d Rewilded mice harbor an altered microbiota including increases in intestinal fungi

No abstract

Mice born by C-section developed increased body weight and lacked microbiota developmental changes observed in control mice.

32The immune systems of free-living mammals such as humans and wild mice display a 33 heightened degree of activation compared with laboratory mice maintained under artificial 34 conditions. Here, we demonstrate that releasing inbred laboratory mice into an outdoor enclosure 35to mimic life in a natural environment alters the state of immunity. In addition to enhancing the 36 differentiation of T cell populations previously associated with pathogen exposure, we found that 37 outdoor release of mice led to an increase in circulating granulocytes. However, rewilded mice 38 were not infected by pathogens previously implicated in immune activation. Rather, changes to 39 the immune system were associated with an altered composition of the microbiota, and fungi 40 isolated from rewilded mice were sufficient to increase circulating granulocytes. These findings 41 establish an experimental procedure to investigate the impact of the natural environment on 42 immune development and identify a role for sustained fungal exposure in determining 43 granulocyte numbers. 44 45 46 48 research and has enabled fundamental advances in basic immunology. Yet, this ubiquitous model 49 fails to recreate certain aspects of human immunity. Inbred laboratory mice and adult humans 50 differ in the proportion of leukocyte subsets, transcriptional responses to microbial challenges, 51 and other immune parameters (Masopust et al., 2017; Tao and Reese, 2017). Such differences 52 may limit the predictive value of experiments with mice when studying complex inflammatory 53 and infectious diseases, resulting in significant shortcomings in translating laboratory 54 observations to humans. 55Recent findings suggest that this shortcoming of the rodent model may be due to the 56 specific pathogen free (SPF) environment in which they are maintained. Wild mice and pet store 57 mice, both of which are exposed to a litany of pathogens that are typically excluded from SPF 58 facilities, display an abundance of differentiated memory T cells that more closely resembles the 59 state of immunity in adult humans (Abolins et al., 2017; Beura et al., 2016; Choi et al., 2019). 60Similarly, transferring embryos from lab mice into wild mice generates commensal-and 61 pathogen-exposed offspring (wildlings) that more faithfully recreate human immunity than 62 standard SPF mice, including the unresponsiveness to immunotherapies that failed in clinical 63 trials (Rosshart et al., 2019). Sequentially infecting SPF mice with 3 viruses and a helminth shifts 64 the gene expression profile of peripheral blood mononuclear cells (PBMCs) towards that of pet 65 store mice and adult humans (Reese et al., 2016), further highlighting the role for pathogen 66 experience in normalizing the immune system. SPF mice are also distinguished from free-living 67 mammals by the lack of exposure to potentially immuno-stimulatory members of the microbiota 68 that are absent in a laboratory animal facility. For example, the offspring of germ-free mice 69 inoculated with ileocecal contents from ...

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of Coronavirus Disease 2019 (COVID-19), a pandemic that has claimed over 700,000 human lives. The only SARS-CoV-2 antiviral, for emergency use, is remdesivir, targeting the viral polymerase complex. PF-00835231 is a pre-clinical lead compound with an alternate target, the main SARS-CoV-2 protease 3CLpro (Mpro). Here, we perform a comparative analysis of PF-00835231 and remdesivir in A549+ACE2 cells, using isolates of two major SARS-CoV-2 clades. PF-00835231 is antiviral for both clades, and, in this assay, statistically more potent than remdesivir. A time-of-drug-addition approach delineates the timing of early SARS-CoV-2 life cycle steps and validates PF-00835231’s time of action. Both PF-00835231 and remdesivir potently inhibit SARS-CoV-2 in human polarized airway epithelial cultures. Thus, our study provides in vitro evidence for the potential of PF-00835231 as an effective antiviral for SARS-CoV-2, addresses concerns from non-human in vitro models, and supports further studies with this compound.